This segment focuses on the research, development, and clinical application of regenerative medicine therapies, with a primary emphasis on Zofin, an acellular biologic therapeutic derived from perinatal sources. Research & Development activities include preclinical studies, Phase I/II clinical trials for COVID-19, and investigations into the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection. The segment leverages technologies such as microRNA analysis, growth factor identification, and exosome characterization. Therapeutic areas include respiratory diseases, viral infections, and degenerative conditions. The goal is to improve patient outcomes by harnessing the regenerative potential of perinatal tissues. Future opportunities involve expanding clinical trials to other indications and developing novel delivery methods for Zofin. Regulatory and clinical aspects are managed in compliance with FDA guidelines.

This segment provides independent education, advertising, and marketing services to medical, healthcare, anti-aging, and regenerative service providers. Activities include developing marketing strategies, creating advertising campaigns, and providing educational resources to healthcare professionals. The segment aims to enhance the visibility and adoption of regenerative medicine practices. Technologies used include digital marketing platforms, content creation tools, and data analytics for campaign optimization. The focus is on promoting evidence-based regenerative medicine and fostering collaboration within the healthcare community. Future opportunities involve expanding the service offerings to include telemedicine and remote patient monitoring solutions. This segment contributes to the overall growth of the regenerative medicine market by supporting healthcare providers in delivering innovative treatments.